Abstract：
OBJECTIVE: The aim of this study is to share our experience in treating patients with LMs over a span of 14 years, evaluating its efficacy and safety, particularly with the use of ethanol as sclerosant of choice.
METHODS: A retrospective review of pediatric patients diagnosed and later treated for LMs between 2008 and 2022 was conducted. We collected patient demographics, LM characteristics, treatment strategies and outcomes, including response to treatment and complications.
RESULTS: The cohort included 36 patients (24 males), first presenting clinically at a median age of 5 months (range 0-12 years). LMs were macrocystic (17), microcystic (3), and mixed types (16). In most patients (22) the malformation involved the cervicofacial area. Twenty-five patients underwent 54 procedures, averaging 2 procedures per patient (range 1-13). Sclerotherapy resulted in 90% of patients exhibiting some response of the LM (p=0.005). Ethanol was used in most procedures (31) and proved most efficacious, facilitating partial or complete response of the malformations in all cases compared to 72% with other sclerosants (p=0.06). Sclerotherapy exhibited low complication rates among all sclerosants used (7%, p=0.74).
CONCLUSIONS: Sclerotherapy is a safe and effective intervention for pediatric LMs. Ethanol demonstrated comparable efficacy and safety to other sclerosants, highlighting its potential as a preferred treatment option. This study supports the tailored use of sclerotherapy, guided by a thorough understanding of the risks and benefits, to provide optimized care for patients with LMs.
METHODS: A retrospective review of pediatric patients diagnosed and later treated for LMs between 2008 and 2022 was conducted. We collected patient demographics, LM characteristics, treatment strategies and outcomes, including response to treatment and complications.
RESULTS: The cohort included 36 patients (24 males), first presenting clinically at a median age of 5 months (range 0-12 years). LMs were macrocystic (17), microcystic (3), and mixed types (16). In most patients (22) the malformation involved the cervicofacial area. Twenty-five patients underwent 54 procedures, averaging 2 procedures per patient (range 1-13). Sclerotherapy resulted in 90% of patients exhibiting some response of the LM (p=0.005). Ethanol was used in most procedures (31) and proved most efficacious, facilitating partial or complete response of the malformations in all cases compared to 72% with other sclerosants (p=0.06). Sclerotherapy exhibited low complication rates among all sclerosants used (7%, p=0.74).
CONCLUSIONS: Sclerotherapy is a safe and effective intervention for pediatric LMs. Ethanol demonstrated comparable efficacy and safety to other sclerosants, highlighting its potential as a preferred treatment option. This study supports the tailored use of sclerotherapy, guided by a thorough understanding of the risks and benefits, to provide optimized care for patients with LMs.
摘要：
目的：这项研究的目的是分享我们在14年治疗LMs患者的经验，评估其疗效和安全性，特别是使用乙醇作为硬化剂的选择。
方法：对2008年至2022年期间诊断并接受LMs治疗的儿科患者进行了回顾性回顾。我们收集了病人的人口统计,LM特性，治疗策略和结果，包括对治疗的反应和并发症。
结果：该队列包括36名患者（24名男性），首次出现在中位年龄5个月（范围0-12岁）的临床上。LMs是大囊性的（17），微囊(3),和混合类型(16)。在大多数患者（22）中，畸形涉及颈面部区域。25名患者接受了54次手术，平均每个患者2个程序（范围1-13）。硬化治疗导致90%的患者表现出LM的一些反应(p=0.005)。乙醇在大多数程序中使用（31），被证明是最有效的，与其他硬化剂相比，在所有情况下促进畸形的部分或完全反应为72％（p=0.06）。在使用的所有硬化剂中，硬化疗法的并发症发生率较低（7%，p=0.74）。
结论：硬化疗法是一种安全有效的儿科LMs干预措施。乙醇显示出与其他硬化剂相当的疗效和安全性，强调其作为首选治疗选择的潜力。这项研究支持定制使用硬化疗法，以对风险和收益的透彻理解为指导，为患有LMs的患者提供优化的护理。
方法：对2008年至2022年期间诊断并接受LMs治疗的儿科患者进行了回顾性回顾。我们收集了病人的人口统计,LM特性，治疗策略和结果，包括对治疗的反应和并发症。
结果：该队列包括36名患者（24名男性），首次出现在中位年龄5个月（范围0-12岁）的临床上。LMs是大囊性的（17），微囊(3),和混合类型(16)。在大多数患者（22）中，畸形涉及颈面部区域。25名患者接受了54次手术，平均每个患者2个程序（范围1-13）。硬化治疗导致90%的患者表现出LM的一些反应(p=0.005)。乙醇在大多数程序中使用（31），被证明是最有效的，与其他硬化剂相比，在所有情况下促进畸形的部分或完全反应为72％（p=0.06）。在使用的所有硬化剂中，硬化疗法的并发症发生率较低（7%，p=0.74）。
结论：硬化疗法是一种安全有效的儿科LMs干预措施。乙醇显示出与其他硬化剂相当的疗效和安全性，强调其作为首选治疗选择的潜力。这项研究支持定制使用硬化疗法，以对风险和收益的透彻理解为指导，为患有LMs的患者提供优化的护理。
